Skip to main content
Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial

Fig. 6

Correlations between changes in NT-proBNP levels (from baseline values to 6-month values) and changes in exercise-induced annular a′ velocity increase (LA reserve, a), exercise-induced e′ velocity increase (diastolic reserve, b), and hsCRP blood levels in the entire empagliflozin group (c) and in the subgroup of patients with baseline hsCRP > 2.1 mg/L (above the median, d). a Average annular relaxation velocity, ε Average annular relaxation velocity, hsCRP High-sensitivity C-reactive protein, LASr Left atrial strain during the reservoir phase, NT-proBNP N-terminal pro–brain natriuretic peptide, sST2 Soluble interleukin 1 receptor-like 1

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840